Mount Yale Investment Advisors LLC Has $1.62 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Mount Yale Investment Advisors LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5.8% in the first quarter, Holdings Channel reports. The institutional investor owned 5,696 shares of the medical research company’s stock after acquiring an additional 311 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Amgen were worth $1,619,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Horizon Financial Services LLC bought a new stake in Amgen in the 1st quarter valued at about $28,000. BOK Financial Private Wealth Inc. acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $29,000. United Community Bank bought a new stake in shares of Amgen in the fourth quarter valued at approximately $29,000. Planned Solutions Inc. acquired a new stake in Amgen during the fourth quarter worth approximately $30,000. Finally, Delos Wealth Advisors LLC increased its stake in Amgen by 2,500.0% during the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after acquiring an additional 100 shares during the period. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on AMGN shares. Truist Financial reissued a “buy” rating and set a $320.00 target price on shares of Amgen in a report on Friday, April 12th. William Blair upgraded shares of Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. Royal Bank of Canada increased their price target on shares of Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a research report on Friday, June 14th. TD Cowen lowered their price objective on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Finally, Barclays raised Amgen from an “underweight” rating to an “equal weight” rating and boosted their price target for the stock from $230.00 to $300.00 in a report on Friday, May 3rd. Ten research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $312.63.

Amgen Trading Down 0.7 %

NASDAQ:AMGN traded down $2.34 during trading hours on Monday, hitting $332.51. 1,582,004 shares of the company were exchanged, compared to its average volume of 2,653,672. The company has a fifty day simple moving average of $313.96 and a 200 day simple moving average of $297.24. Amgen Inc. has a one year low of $228.21 and a one year high of $346.85. The stock has a market capitalization of $178.37 billion, a price-to-earnings ratio of 47.57, a price-to-earnings-growth ratio of 2.78 and a beta of 0.58. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.76 by $0.20. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The business had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.45 billion. During the same period in the prior year, the business posted $3.98 earnings per share. The firm’s revenue was up 22.0% on a year-over-year basis. Sell-side analysts expect that Amgen Inc. will post 19.5 EPS for the current fiscal year.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.